pioglitazone has been researched along with riluzole in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Benecke, R; Bogdahn, U; Dengler, R; Dreyhaupt, J; Dupuis, L; Fischer, W; Grehl, T; Grosskreutz, J; Heneka, MT; Hermann, A; Kassubek, J; Lindauer, E; Ludolph, AC; Meyer, T; Otto, M; Schrank, B; Steiner, F; Wessig, C; Winkler, AS; Zierz, S | 1 |
| Dengler, R; Dieterlé, S; Dreyhaupt, J; Dupuis, L; El Oussini, H; Fischer, W; Grehl, T; Grosskreutz, J; Hermann, A; Kassubek, J; Ludolph, AC; Meyer, T; Scekic-Zahirovic, J; Sinniger, J; Spreux-Varoquaux, O; Van Den Bosch, L; Vercruysse, P; Witting, A; Zierz, S | 1 |
1 review(s) available for pioglitazone and riluzole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for pioglitazone and riluzole
| Article | Year |
|---|---|
A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis.
Topics: Aged; Amyotrophic Lateral Sclerosis; Animals; Anticonvulsants; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Mice; Middle Aged; Pioglitazone; Riluzole; Survival Rate; Thiazolidinediones | 2012 |
Alterations in the hypothalamic melanocortin pathway in amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Female; Humans; Hypothalamus; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pioglitazone; Pro-Opiomelanocortin; Riluzole; Signal Transduction; Superoxide Dismutase; Superoxide Dismutase-1; Thiazolidinediones | 2016 |
5 other study(ies) available for pioglitazone and riluzole
| Article | Year |
|---|---|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |